Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

This study has been completed.
Information provided by (Responsible Party):
Marc Lallemant, Institut de Recherche pour le Developpement Identifier:
First received: September 1, 2005
Last updated: January 4, 2012
Last verified: January 2012